Actively Recruiting
Evaluation of Safety, Immune Response, and Dose Levels of mRNA-1365 Vaccine Against RSV and hMPV in Healthy Adults 60 Years and Older
Led by ModernaTX, Inc. · Updated on 2026-08-19
375
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, reactogenicity, and immune response of several doses of the investigational vaccine mRNA-1365 Profile 2, which targets Respiratory Syncytial Virus RSV and Human Metapneumovirus hMPV. This Phase 1 study includes healthy adults aged 60 years and older and aims to understand how different vaccine doses affect participants. Participants will be randomly assigned to receive a single injection of either one of three dose levels of mRNA-1365 Profile 2 or one of two comparator vaccines, mRNA-1345 Profile 1 or mRNA-1345 Profile 3, all given on Day 1. The study uses a staggered dose-escalation design and is open-label with observer-blind expansion, meaning participants and observers are blinded to assignment while some staff know the dosing. Throughout the study, participants will be monitored for local and systemic reactions for up to 7 days after vaccination, and for any adverse events up to 28 days and serious or medically attended adverse events up to 181 days. Researchers will measure neutralizing antibody levels on Day 29 to assess immune response. The trial will last until July 2027, with participants expected to attend scheduled visits for safety assessments and blood tests to evaluate vaccine effects.
CONDITIONS
Brief Title
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
Research Team
M
Moderna WeCareTeam
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here